Val16Ala polymorphism and its effects on chemoprevention
| Regression | No regression | OR (95% CI; regression vs no regression) | Progression | No progression | OR (95% CI; progression vs no progression) | |
|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | |||
| H. pylori treatment | ||||||
| Val/Val | 109 (69.4) | 533 (73.3) | 1.00 | 284 (72.3) | 358 (72.9) | 1.00 |
| Val/Ala+Ala/Ala | 48 (30.6) | 194 (26.7) | 1.06 (0.71-1.58)* | 109 (27.7) | 133 (27.1) | 1.07 (0.79-1.45)* |
| Garlic supplementation | ||||||
| Val/Val | 170 (71.4) | 851 (74.8) | 1.00 | 429 (74.0) | 592 (74.5) | 1.00 |
| Val/Ala+Ala/Ala | 68 (28.6) | 286 (25.2) | 1.13 (0.81-1.56)† | 151 (26.0) | 203 (25.5) | 1.07 (0.83-1.38)† |
| Vitamin supplementation | ||||||
| Val/Val | 147 (69.0) | 863 (74.1) | 1.00 | 431 (75.1) | 579 (72.0) | 1.00 |
| Val/Ala+Ala/Ala | 66 (31.0) | 302 (25.9) | 1.28 (0.92-1.07)‡ | 143 (24.5) | 225 (28.0) | 0.83 (0.64-1.06)‡ |
↵*Adjusted for age, gender, H. pylori infection, smoking status, drinking status, baseline pathology, garlic supplementation, and vitamin supplementation.
↵†Adjusted for age, gender, H. pylori infection, smoking status, drinking status, baseline pathology, H. pylori treatment, and vitamin supplementation.
↵‡Adjusted for age, gender, H. pylori infection, smoking status, drinking status, baseline pathology, H. pylori treatment, and garlic supplementation.